These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29607153)

  • 1. Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer.
    Pang C; Yin L; Zhou X; Lei C; Tong R; Huang M; Gong Y; Ding Z; Xue J; Zhu J; Wang Y; Ren L; Zhou L; Wang J; Peng F; Zhou Q; Lu Y
    J Thorac Dis; 2018 Feb; 10(2):816-824. PubMed ID: 29607153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma.
    Nambirajan A; Husain N; Shukla S; Kumar S; Jain D
    Indian J Med Res; 2019 Oct; 150(4):376-384. PubMed ID: 31823919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.
    Fujimoto D; Sato Y; Uehara K; Ishida K; Fukuoka J; Morimoto T; Kawachi H; Mori R; Ito M; Teraoka S; Nagata K; Nakagawa A; Otsuka K; Imai Y; Tomii K
    J Thorac Oncol; 2018 Mar; 13(3):377-386. PubMed ID: 29233789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
    Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B
    BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma.
    Chun HW; Hong R
    Oncol Lett; 2019 Jun; 17(6):5487-5498. PubMed ID: 31186768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
    Parra ER; Villalobos P; Mino B; Rodriguez-Canales J
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
    Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
    Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer.
    Lee SE; Park HY; Lim SD; Han HS; Yoo YB; Kim WS
    J Breast Cancer; 2020 Jun; 23(3):303-313. PubMed ID: 32595992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Three Clones of PD-L1 in Lung Cancer: A Single-center Experience.
    Park SG; Lee HJ; Lee SB; Hong R
    In Vivo; 2023; 37(1):233-241. PubMed ID: 36593005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
    Capizzi E; Ricci C; Giunchi F; Zagnoni S; Ceccarelli C; Gómez BUÁ; Casolari L; Gelsomino F; Trisolini R; Fiorentino M; Ardizzoni A
    Lung Cancer; 2018 Dec; 126():9-14. PubMed ID: 30527198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay.
    Gupta G; Pasricha S; Kamboj M; Sharma A; Nayana NS; Durga G; Sharma A; Rawal S; Meh A
    Indian J Pathol Microbiol; 2022; 65(4):839-843. PubMed ID: 36308190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
    McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
    JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
    Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
    Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.
    Lantuejoul S; Damotte D; Hofman V; Adam J
    J Thorac Dis; 2019 Jan; 11(Suppl 1):S89-S101. PubMed ID: 30775032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic significance of PD-L1 expression as a potential predictor of survival in gastric cancer].
    Sotnikova TN; Danilova NV; Polushkina TV; Malkov PG; Chayka AV; Khomyakov VM; Kalinin DV
    Arkh Patol; 2023; 85(4):18-23. PubMed ID: 37530186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
    Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
    Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.